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The use of intravaginal brachytherapy
as a post-operative procedure to reduce the
incidence of reccurence of carcinoma of the
endometrium is well known. We analysed 3
differents methods of intravaginal
brachytherapy: conventional brachytherapy Ra-
226, LDR after-loading technic Cez 137 and
HDR after-loading brachytherapy Irydium 192.
In the period 1953 -1986 in Gynaecological
Radiotherapy Department in Poznan,
brachytherapy with vaginal applicators
containing 30 mg radium, filtrated by 2 mm Pb,
were used after total hysterectomy.Thegiven
dose was 3000 mgh in 100 hours of one
insertion. Since 1986 Caesium 137 in one
oblong applicator has been used to fill the
vagina. Usualy four sources were employed and
treatment time was about 24 hours. On the basis
of the radiological verification in two planes, the
doses were calculated at 0,5 em from the
applicator surface and at the contact point of the
contrast image of the Foley catheter placed in the
bladder neck. Dose in the rectum was calculated
at the distance shown by a marker situated in the
rectum. The patients were treated to the total
dose of 30 Gy. From 1995 HDR after-loading
inreasingly replaced LDR after-loading in
intravaginal brachytherapy. With iridium 192 the
overall dose was applied in three fractions- each
6Gy calculated at 0,5 em from the surface of the
oblong applicator. Complications were graded
with EORTC\ RTOG criteria.
CHEMORADIOTHERAPY OF ANAL CANCER - A REPORT OF 12 CASES
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Between 1991 and 1996, 12 patients (9
males and 3 females) with squamous-cell anal
carcinoma, stage TI-3 NO-3MO, were treated at
our institution with concomitant chemotherapy and
radiation. Median age of patients was 57 years
(range 38-70 years.)
Ten patients received radiotherapy to the
pelvis and inguinal lymph nodes at the dose of 30
Gy. After planned interval (average 11 days),
patients received a bost of 16-20 Gy to the tumor.
Two remaining patients were irradiated to the
pelVis (50 Gy in one patient, 45 Gy and then boost
of 15 Gy in the second one). Daily doses of 1.8 to
2.0 Gy, 5 times per week, were used.
Concomitant chemotherapy included Mitomycin C
(10-15 mg/m2, day 1) and 5 Fluorouracil (750
mg/m2, days 1-4 or 1-5) delivered at the beginning
(twelve pts) or at the beginning and at the end of
treatment (seven pts).
In the patients (83%) complete clinical
remission (CR) was achieved, confirmed by
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negative biopsy from the site of primary tumour in
five cases. All patients with CR remain free of
disease for a median of 18 months (range: 7-70
months).
Surgery (abdomino-perineal resection)
was performed in the two patients who achieved
only partial response. One of them remains free of
disease 48 months after chemoradiotherapy and
the another is alive with disease dissemination to
the liver, which occured 9 months after completion
of radiotherapy.
Treatment tolerance was acceptable.
Three patients experienced WHO grade 3
neutropenia. Late complications were observed in
three patients (25%) and included intermittent
stool incontinence (two pts) and erection disorders
(one pt).
The results of this analysis remain in
accordance with the literature data and confirm
the role of conservative management of anal
cancer.
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